

EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(incorporated in Bermuda with limited liability) (Stock Code: 00858)

ANNOUNCEMENT

This announcement is made at the request of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). The board of directors (the "**Board**") of Extrawell Pharmaceutical Holdings Limited (the "**Company**") has noted today's increases in the share price and trading volume of the shares of the Company.

The Company and its subsidiaries (collectively, the "**Group**") are in the course of negotiating with independent third parties in relation to a proposed cooperation for the establishment of a manufacturing plant in the People's Republic of China for the production of the Group's products. Such proposed cooperation is still at its negotiation stage and no agreement has been reached by the parties at this stage. The proposed cooperation may or may not constitute a notifiable transaction under Chapter 14 of the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules").

Save as aforesaid, the Board is not aware of any reasons for such increases in the share price and trading volume of the shares of the Company.

Further announcement(s) will be made if necessary pursuant to the Listing Rules.

Save for the above, the Board confirms that there are no negotiations or agreements relating to intended acquisition or realizations which are discloseable under Rule 13.23 of the Listing Rules, neither is the Board aware of any matter discloseable under the general obligation imposed by Rule 13.09 of the Listing Rules, which is or may be of a price-sensitive nature.

The proposed cooperation may or may not proceed. Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the shares of the Company.

As at the date of this announcement, the Board comprised five executive Directors, namely Dr. Mao Yu Min, Mr. Ho Chin Hou, Mr. Ho Yu Ling, Mr. Li Qiang and Dr. Xie Yi; and three independent non-executive Directors, namely Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

By order of the Board Extrawell Pharmaceutical Holdings Limited Ho Yu Ling Executive Director

Hong Kong, 5 October 2006

* For identification only

Please also refer to the published version of this announcement in The Standard.